1) Adenoids are lymphoid tissue located in the nasopharynx that develop in utero and enlarge between ages 3-5 before involuting at puberty. 2) Acute and chronic nasopharyngitis can be caused by viral or bacterial infections and cause symptoms like nasal obstruction, discharge, and ear complaints. 3) Rare tumors of the nasopharynx include juvenile nasopharyngeal angiofibroma, which is a benign but locally invasive tumor seen in adolescent males.

1. DISEASES OF
NASOPHARYNX
DEPT OF OTORHINOLARYNGOLOGY
JJM M C
DAVANAGERE

2. ADENOIDS
Adenoids are also called as
nasopharyngeal tonsil
Situated at junction of the roof and
posterior wall of the nasopharynx
Composed of vertical ridges of lymphoid
tissue separated by deep clefts and
covered by ciliated columnar epithelium
Adenoids have no crypts and no capsule
unlike palatine tonsil
consists of B and T-lymphocytes

3. DEVELOPMENT
Development starts at 16th week of intra-
uterine life
Clinically not present at 1st month after
birth
Adenoids are identifiable by 4th month-2
yrs
Hypertrophy/hyperplasia starts at 3-5
years of age
Involutes at puberty

4. CLINICAL IMPORTANCE
1ST month after birth any mass in
nasopharynx – Encephalocoele should be
suspected
Absence or decrease in size of adenoids
at 4months-2years
hypogammaglobenemia / wiskot-aldrich
syndrome should be suspected
Ectopic hypophysis-remnant rathke’s
pouchchronophil adenoma in females
after 50 yeras

5. ADENOID HYPERPLASIA /
ADENOIDITIS - ETIOLOGY
Physiological enlargement 3-5 years of age
(some children develop generalized lymphoid
hyperplasia)
Recurrent attacks of rhinitis, sinusitis, tonsillitis
Allergy of upper respiratory tract

6. CLINICAL FEATURES
NASAL SYMPTOMS
 Nasal obstruction
 Nasal discharge
 Sinusitis (commonly chronic maxillary
sinusitis)
 Epistaxis
 Voice change

7. CLINICAL FEATURES
EAR COMPLAINTS
 Tubal obstruction
 Recurrent attacks of acute otitis media
 Chronic suppurative otitis media and
serous otitis media

8. CLINICAL FEATURES
Adenoid facies: elongated face with dull
expression, open mouth, prominent and
crowded teeth, hitched up upper lip,
pinched in appearance of nose, high
arched palate
Pulmonary hypertension / cor-pulmonale

9. DIAGNOSIS
Posterior rhinoscopic examination
difficult to perform in children
Rigid or flexible nasopharyngoscopy
X-ray lateral view of the nasopharynx
Detailed nasal examination to be
conducted to rule out other causes of
nasal obstruction

10. TREATMENT
When symptoms are not marked
breathing exercises, decongestant nasal
drops, antihistaminics, antibiotics can be
used
When symptoms are marked
adenoidectomy is done

11. ACUTE NASOPHARYNGITIS
Etiology: may be due to isolated infection
or secondary to generalized upper
respiratory tract infection
Viruses: influenza, para-influenza, rhino
virus, adeno virus
Bacteria: streptococci, pneumococcus,
haemophilus influenzae

12. ACUTE NASOPHARYNGITIS
Clinical features:
 Dryness and burning sensation of the
throat above soft palate
 Pain and discomfort localized to the back
of nose with some difficulty in swallowing
 In severe infections there is fever and
enlarged cervical lymph nodes
 Examination reveals congested and
swollen mucosa often covered with whitish
exudate

13. ACUTE NASOPHARYNGITIS
Treatment:
 Mild cases: spontaneous recovery seen.
Analgesics may be used to relieve pain
 Severe cases require systemic antibiotics
 If associated with adenoids topical
decongestant drops can be used

14. CHRONIC NASOPHARYNGITIS
Etiology : associated with chronic
infections of nose, paranasal sinuses and
pharynx
Commonly seen in heavy smokers,
drinkers and those exposed to dust and
fumes

15. CHRONIC NASOPHARYNGITIS
Clinical features:
postnasal discharge with irritation at the back of
the nose is most common complaint
Patient will have consistent desire to clear throat
by hawking or inspiratory snorting
Examination of nasopharynx reveals congested
mucosa and mucopus or dry crusts
In children adenoids are often enlarged and
infected

16. CHRONIC NASOPHARYNGITIS
Treatment:
chronic infections of the nose, paranasal
sinuses and oropharynx should be treated
Smoking and drinking should be stopped
Avoid dust and fumes
Alkaline nasal douche to remove crusts
and mucopus
Steam inhalation

17. THORNWALDT’S DISEASE
(PHARYNGEAL BURSITIS
It is infection of pharyngeal bursa which is
a median recess representing attachment
of notochord to endoderm of primitive
pharynx
It is located in the posterior wall of
nasopharynx in the adenoid mass

18. THORNWALDT’S DISEASE
(PHARYNGEAL BURSITIS
Clinical features:
Persistent post nasal discharge with crusting in
nasopharynx
Nasal obstruction
Tubal obstruction and resulting serous otitis
media
Dull type of occipital headache
Recurrent sore throat
Low grade fever
Examination reveals a cystic and fluctuant swelling
Posterior wall of nasopharynx

19. THORNWALDT’S DISEASE
(PHARYNGEAL BURSITIS
Treatment:
Antibiotics
Marsupialisation of cystic swelling and
adequate removal of its lining membrane

20. TUMORS OF NASOPHARYNX
JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
It is a benign tumor of nasopharynx
Exact etiology is not known
It is a rare tumor
Seen in adolescent males in 2nd decade of
life (most commonly at age of 14 years
with range 7-19 years)
Its growth is thought to be testosterone
dependent

21. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Pathogenesis
 Ringertz (1938): inequalities in growth of skull
bones result in hypertrophy of underlying
periosteum in response to hormonal influence
 Ewing (1941): arises from embrygenic fibro-
cartilage between basi-occiput and basi-
sphenoid
 Burner (1942): suggested origin from conjoined
pharyngo-basilar and bucco-pharyngeal fascia
 Osborn (1973): either from hamartomas or fetal
erectile tissue hormonal influence
 Girgis (1973): undifferentiated epithelial cells 
linked to paraganglianomas

22. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Origin of tumor: still now it is a matter of
debate it is believed to arise from the posterior
part of nasal cavity close to the superior margin
of sphenopalatine foramen
Pathology: Gross firm, lobulated, pink to white.
It has no capsule
Microscopy composed of vascular spaces of
varying sizes and shape. It contains fibrous
stroma, thin walled sinusoids, lined by flattened
epithelium absent muscular coat

23. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Extension of the tumor- it is benign and locally invasive
 Nasal cavity: causes obstruction, epistaxis, nasal
discharge
 Paranasal sinuses
 Pterygo-maxillary fissure, infratemporal fossa
 May involve orbit including inferior and superior orbital
fissures
 Cranial cavity: middle fossa commonly involved through
erosion of foramen lacerum. Tumor lies lateral to carotid
artery, cavernous sinus
 It may extend to sphenoid sinus into sella tursica where it
lies medial to carotid artery
 May extend to anterior cranial fossa through ethmoidal
roof or cribriform plate

24. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Clinical features:
 Age/sex: 14-19 year/male
 Most commonly patient presents with recurrent
epistaxis or profuse epistaxis
 Progressive nasal obstruction
 Conductive hearing loss: SOM
 Mass in nasopharynx on examination which is sessile,
smooth, lobulated, pink or whitish, firm (should not be
palpated)
 Broadening of nasal bridge, proptosis, cheek swelling,
infra-temporal involvement, II to VI nerves involvement

26. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Investigations:
 X-ray: soft tissue lateral view of nasopharynx,
paranasal sinuses, skull base
 CT/MRI: anterior bowing of posterior wall of
maxillary sinus, erosion of sphenoid sinus and
greater wing of sphenoid, extension into
pterygopalatine and infra-temporal fossa
 Angiography (digital subtraction angiography) of
carotid artery
 Biopsy is no longer justifiable

27. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Differential diagnosis (diagnosis is rarely
doubtful)
 Antro - choanal polyps
 Large adenoid
 Chondromas

28. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Treatment: only surgical
Various surgical approaches depending
on origin and extension
 Trans-palatal
 Trans-palatal + sublabial approach
 Lateral rhinitomy
 Mid-facial degloving approach
 Infra-temporal fossa approach
Radiotherapy is reserved for extensive intra-
cranial extension and recurrent tumors

30. JUVENILE NASOPHARYNGEAL
ANGIOFIBROMA
Treatment: hormonal therapy can be given
to reduce Vascularity of tumor pre-
operatively
Stilbesterol 2.5mg TID for 3 weeks prior to
surgery
Embolization of feeding vessels is done
prior to surgery to reduce bleeding

31. OTHER BENIGN TUMORS OF
NASOPHARYNX
Teratomas: seen at birth
Pleomorphic adenoma
Chordoma
Hamartoma (malformed normal tissue)
 haemangioma
Choristoma: mass of normal tissue in
abnormal site
paraganglianomas

32. MALIGNANT TUMORS OF
NASOPHARYNX NASOPHARYNGEAL
CARCINOMA
Incidence- common in china particularly in
southern states and Taiwan. It is
uncommon in India and constitutes 0.5%
of all cancers
Incidence if nasopharyngeal cancer in
china is 30-50/100000 population
Sex: male: female = 2-3 : 1
Age: in Chinese risk starts by 15-19 yrs of
age. Average age group is 25-64 years

33. NASOPHARYNGEAL CARCINOMA
Aetiology
 Genetic: Chinese have higher genetic
susceptibility (even in migrants)
 Environmental: air pollution, smoking,
nitrosamines from dry salted fish, smoke from
burning incense and wood
 Occupation: wood workers, foresters, welders,
coal workers, metal workers are commonly
effected
 Viral: epstein-barr virus- Ig A is the serological
marker. It is elevated months or years prior to
the clinical onset
 Epithelial tumor cells have intimate relation with
T-lymphocytes which are CD-8 positive

34. NASOPHARYNGEAL CARCINOMA-
NATURAL HISTORY
Inception
Genetic, environmental, viral
factors
silent period
Systemic spread
Focal invasion
Blood stained mucus, ET Parapha
blockage ryngeal,
skull
base
Primary lymph node Locoregional
station retropharyngeal spread

35. NASOPHARYNGEAL CARCINOMA
• Histopathology: squamous cell carcinoma
 Well differentiated
 Moderately differentiated
 Poorly differentiated
• Non-keratinizing carcinoma: transitional cell
carcinoma
• Undifferentiated carcinoma
 Lymphoepithelioma
 Anaplastic carcinoma
 Spindle cell carcinoma
 Clear cell carcinoma

36. NASOPHARYNGEAL CARCINOMA
Gross appearance
 Proliferative
 Ulcerative
 Infiltrative
 Commonest site: lateral wall, fossa of
Rosenmuller

37. W.H.O CLASSIFICATION
Epithelial tumors: benign, malignant
Soft tissue: benign, malignant
Malignant lymphomas
Tumors of bone and cartilage
Miscellaneous tumors: benign and
malignant
Secondary tumors
Tumor like lesions

39. CLINICAL FEATURES
Age: 50-70 years (in India)
35-64 years (in Chinese)
Sex: M : F:: 2-3 : 1
Symptoms
 Nasal: obstruction, discharge, denasal speech,
epistaxis
 Otological: eustachian tube obstruction, conductive
deafness, tinnitus, dizziness, otalgia
 Ophthalmo-neurological: VI nerve involvement
results in squint and diplopia, III, IV, V nerve
involvement results in ophthalmoplegia, facial
nerve involvement results in absent corneal reflex,
horner’s syndrome

40. CLINICAL FEATURES
 Neck: painless lymph node most
commonly jugulo-digastric, spinal
accessory (posterior triange node
 Distant metastasis: thoraco lumbar spine,
liver, lungs

42. DIAGNOSIS
Posterior rhinoscopy
Fibro-optic endoscopy
Rigid endoscope
Examination under general anaesthesia
Biopsy
X-ray skull
CT- scan

43. STAGING-AJCC (1992)

44. STAGING-AJCC (1992)

45. TREATMENT
Radiotherapy: treatment of choice,
megavoltage radiation of 6000-7000 rads
Brachytherapy:
 Rapid fall of radiation at short distance
 Higher dose
 Spares neighboring structures
 Trans nasal intra cavity brachytherapy
using iridium 192

46. TREATMENT
Surgery: plays minor role. It is limited to radical neck dissection
for radio resistant nodes and post reduction salvage surgery for
recurrent tumors
Approaches:
 Trans nasal-maxillary
 Lateral rhinotomy
 Leforte-I osteotomy
 Extended subtotal maxillectomy
 Transpalatal
 Mid facial degloving
 Maxillary swing
 Mandibular swing
 Infra temporal fossa approach
 Trans pharyngeal, trans temporal, trans cervical

47. RESULTS
Depends on histological type, stage, age,
sex, presence of nodes
905 recurrence in 2-3 years
Survival rate: 40-50% (5 years)
Better outcome in patients below 40 years
of age